

Nucala (Mepolizumab) for CRSwNP EXCEPTION DRUG STATUS (EDS) REQUEST FORM

Fax: (204) 942-2030 or 1-877-208-3588

Prescriber Name:				Fax Number:		
Prescriber Address:				Phone Number:		
				Prescriber License Number (NOT Billing Number):		
Patient First Name:	PHIN	PHIN: MHS		MHSC:		
Patient Last Name:	Patie	Patient's Date of Birth:				
New Request	Renewal Request					
Medication, Strength, and Dosage Fo	Regimen and Duration:					
Exception Drug Status (EDS) approval i provide the following details about how t support this EDS request.						
For INITIAL Requests:						
	Severe chronic rhinosinusitis with nasal polyps (CRSwNP)					
Diagnosis/Indication: Other:		:				
Please check YES or NO to the follow	wing statements:					
Request for coverage is being made by a physician with expertise in managing severe			ere C	CRSwNP.	YES	NO
Patient has endoscopically or CT-documented bilateral nasal polyps.					YES	NO
Patient has undergone at least 1 prior surgical intervention for nasal polyps			<u> </u>		YES	NO
Patient is tolerant and able to continue use of inhaled nasal corticosteroids but inhaled nasal corticosteroids for 3 months at maximally tolerated doses .				ut has refractory symptoms despite use of YES N		
Please specify the inhaled nasal corticosteroid the patient is currently using:						
Nucala (mepolizumab) will be used as add-on maintenance treatment with intranasal				rticosteroids.	YES	NO
Please provide the current score for	at least ONE of the fol	lowing tests:				
Sino-nasal Outcome Test-22 (SNOT-22):			Date of Result:			
Endoscopic nasal polyp score (NPS):			Date of Result:			
Additional Relevant Clinical Informat	tion:					
For RENEWAL Requests:						
Please provide the current score for	at least ONE of the fol	lowing tests:				
Sino-nasal Outcome Test-22 (SNOT-22):			Date of Result:			
Endoscopic nasal polyp score (NPS):			Date of Result:			
Prescriber Signature and Date:						
Please check the following:						
I have discussed with the patien Exception Drug Status for presc		asing their informatio	on to	Manitoba Health, Seniors and Lo	ong-Term Care is to	obtain
Date:	Prescriber Signatu	Prescriber Signature:				
1		ı				